Factor XIII B Recombinant Rabbit Monoclonal Antibody (105), Invitrogen™

Description

• This product is preservative free
• It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%)
• Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
• The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
• Then, individual clones are screened to select the best candidates for production
• The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
• This antibody has specificity for Human Coagulation Factor XIII B chain/F13B
• This gene encodes coagulation factor XIII B subunit
• Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade
• Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits
• The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as a plasma carrier molecules
• Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin
• Upon activation by the cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII
• This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot
• Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone
• These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.